JAK2 and neoplasm: To sum up, our findings indicate that silencing BCAP31 in TAM can remarkably inactivate the JAK2-STAT3 signaling pathway in tumor cells and enhance the effector function of CD8+ T cells, serving as a promising therapeutic strategy in NB.